A Study of PTS for Patients With Solid Tumors
The primary objective of this study is to determine the MTD of PTS following local and intratumoral injections over a treatment course of two 5-day cycles to patients with palpable advanced solid malignancies who have failed standard treatment.
Solid Tumor
DRUG: Para-toluenesulfonamide Injection (PTS)
Maximum tolerable dose, Maximum tolerable dose, 4 weeks post-treatment
The study will be an open, uncontrolled, single-center, phase I study to assess the safety and tolerability of local intra-tumoral injection 2.0ml (660mg), 4.0ml (1220mg), 6.0ml (1880mg) and 8.0ml (2440mg) PTS in female breast cancer patients.